TNGX Tango Therapeutics, Inc.
USHealthcareAs of 2026-08-24
Why TNGX matters now
Tango Therapeutics, Inc. (TNGX) is a US stock in Healthcare. The latest InvestLog snapshot shows $24.51 with +2.64% on the session and $3.99B in market capitalization; recent performance reads 1-month +37.78% and YTD +215.69%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-45.5M, and EPS of $-0.32. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -4.1%.
The latest indexable market news headline is "Tango Therapeutics: Promising Early Data, But A Long Road Ahead" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $38.00; recent insider activity includes Lee Sung filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
10.26
P/S
61.07
EV/EBITDA
-31.91
DCF Value
$-13.83
FCF Yield
-4.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.3%
Operating Margin
-206.2%
Net Margin
-188.2%
ROE
-41.5%
ROA
-24.6%
ROIC
-27.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-45.5M | $-0.32 |
| Q4 2025 | $0.00 | $-38.7M | $-0.30 |
| FY 2025 | $62.4M | $-101.6M | $-0.87 |
| Q3 2025 | $53.8M | $15.9M | $0.14 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$42.70
Target (Median)
$38.00
Target Range
$24.00 - $69.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.19
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.